Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study
- PMID: 21752435
- PMCID: PMC3336961
- DOI: 10.1016/j.ygyno.2011.06.022
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study
Abstract
Objective: Patients with persistent/recurrent epithelial ovarian cancer/primary peritoneal cancer (EOC/PPC) have limited treatment options. AKT and PI3K pathway activation is common in EOC/PPC, resulting in constitutive activation of downstream mTOR. The GOG conducted a phase II evaluation of efficacy and safety for the mTOR inhibitor, temsirolimus in EOC/PPC and explored circulating tumor cells (CTC) and AKT/mTOR/downstream tumor markers.
Methods: Eligible women with measurable, persistent/recurrent EOC/PPC who had received 1-3 prior regimens were treated with 25mg weekly IV temsirolimus until progression or intolerable toxicity. Primary endpoints were progression-free survival (PFS) ≥6-months, tumor response, and toxicity. CellSearch® system was used to examine CTC, and AKT/mTOR/downstream markers were evaluated by archival tumor immunohistochemistry. Kendall's tau-b correlation coefficient (r) and Cox regression modeling were used to explore marker associations with baseline characteristics and outcome.
Results: Sixty patients were enrolled in a two-stage sequential design. Of 54 eligible and evaluable patients, 24.1% (90% CI 14.9%-38.6%) had PFS ≥6 months (median 3.1 months), 9.3% (90% CI 3.7%-23.4%) experienced a partial response. Grade 3/4 adverse events included metabolic (8), gastrointestinal (8), pain (6), constitutional (5) and pulmonary (4). Suggested associations were between cyclin D1 and PFS ≥6 months, PFS or survival; positive CTC pre-treatment and lack of response; and high CTC expression of M30 and PFS ≥6 months/longer PFS.
Conclusions: Temsirolimus appears to have modest activity in persistent/recurrent EOC/PPC; however, PFS is just below that required to warrant inclusion in phase III studies in unselected patients. Cyclin D1 as a selection marker and CTC measures merit further study.
Trial registration: ClinicalTrials.gov NCT00429793.
Published by Elsevier Inc.
Conflict of interest statement
The authors wish to report that there are no conflicts of interest.
Figures



Similar articles
-
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.Gynecol Oncol. 2011 Jun 1;121(3):455-61. doi: 10.1016/j.ygyno.2011.02.013. Epub 2011 Mar 17. Gynecol Oncol. 2011. PMID: 21414654 Free PMC article. Clinical Trial.
-
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol. 2012 Oct;127(1):70-4. doi: 10.1016/j.ygyno.2012.06.009. Epub 2012 Jun 16. Gynecol Oncol. 2012. PMID: 22710075 Free PMC article. Clinical Trial.
-
A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol. 2012 Jun;125(3):635-9. doi: 10.1016/j.ygyno.2012.03.023. Epub 2012 Mar 22. Gynecol Oncol. 2012. PMID: 22446624 Free PMC article. Clinical Trial.
-
The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.Gynecol Oncol. 2021 Nov;163(2):433-444. doi: 10.1016/j.ygyno.2021.07.008. Epub 2021 Jul 10. Gynecol Oncol. 2021. PMID: 34253390
-
Current and future role of circulating tumor cells in patients with epithelial ovarian cancer.Eur J Surg Oncol. 2016 Dec;42(12):1772-1779. doi: 10.1016/j.ejso.2016.05.010. Epub 2016 May 25. Eur J Surg Oncol. 2016. PMID: 27265041 Review.
Cited by
-
Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer.Cancer Manag Res. 2021 Apr 8;13:3081-3100. doi: 10.2147/CMAR.S292992. eCollection 2021. Cancer Manag Res. 2021. PMID: 33854378 Free PMC article. Review.
-
Circulating Tumor Cells: How Far Have We Come with Mining These Seeds of Metastasis?Cancers (Basel). 2024 Feb 17;16(4):816. doi: 10.3390/cancers16040816. Cancers (Basel). 2024. PMID: 38398206 Free PMC article. Review.
-
Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment.Cancers (Basel). 2021 Dec 11;13(24):6231. doi: 10.3390/cancers13246231. Cancers (Basel). 2021. PMID: 34944851 Free PMC article. Review.
-
Sucrose Non-Fermenting Related Kinase Expression in Ovarian Cancer and Correlation with Clinical Features.Cancer Invest. 2017 Aug 9;35(7):456-462. doi: 10.1080/07357907.2017.1337781. Epub 2017 Jul 19. Cancer Invest. 2017. PMID: 28722495 Free PMC article.
-
Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer.Cancer Drug Resist. 2021 Apr 14;4(3):573-595. doi: 10.20517/cdr.2021.05. eCollection 2021. Cancer Drug Resist. 2021. PMID: 35582310 Free PMC article. Review.
References
-
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
-
- Guppy AE, Nathan PD, Rustin GJ. Epithelial ovarian cancer: a review of current management. Clin Oncol (R Coll Radiol) 2005;17:399–341. - PubMed
-
- Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol. 2006;33:S3–S11. - PubMed
-
- Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424–430. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous